Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
Market Analysis and Insights: Global Adalimumab Market
The global Adalimumab market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Adalimumab Scope and Segment
The global Adalimumab market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Adalimumab market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
The major regions covered in the report are North America, Europe, Asia-Pacific, South America, Middle East & Africa, etc. The report has specifically covered major countries including U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. It includes revenue and volume analysis of each region and their respective countries for the forecast years. It also contains country-wise volume and revenue from the year 2016 to 2021. Additionally, it provides the reader with accurate data on volume sales according to the consumption for the same years.
By the product type, the market is primarily split into
Adalimumab
Adalimumab Biosimilar
By the end users/application, this report covers the following segments
Adults
Children
Competitive Landscape:
The report provides a list of all the key players in the Adalimumab market along with a detailed analysis of the strategies, which the companies are adopting. The strategies mainly include new product Developments, research, and Developments, and also provides revenue shares, company overview, and recent company Developmentss to remain competitive in the market.
The Adalimumab key manufacturers in this market include:
AbbVie
Amgen
Sandoz
Boehringer Ingelheim
Mylan
Biogen
Market Analysis and Insights: Global Adalimumab Market
The global Adalimumab market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Adalimumab Scope and Segment
The global Adalimumab market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Adalimumab market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
The major regions covered in the report are North America, Europe, Asia-Pacific, South America, Middle East & Africa, etc. The report has specifically covered major countries including U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. It includes revenue and volume analysis of each region and their respective countries for the forecast years. It also contains country-wise volume and revenue from the year 2016 to 2021. Additionally, it provides the reader with accurate data on volume sales according to the consumption for the same years.
By the product type, the market is primarily split into
Adalimumab
Adalimumab Biosimilar
By the end users/application, this report covers the following segments
Adults
Children
Competitive Landscape:
The report provides a list of all the key players in the Adalimumab market along with a detailed analysis of the strategies, which the companies are adopting. The strategies mainly include new product Developments, research, and Developments, and also provides revenue shares, company overview, and recent company Developmentss to remain competitive in the market.
The Adalimumab key manufacturers in this market include:
AbbVie
Amgen
Sandoz
Boehringer Ingelheim
Mylan
Biogen
1 Adalimumab Market Overview
1.1 Adalimumab Product Overview
1.2 Adalimumab Market Segment by Type
1.2.1 Adalimumab
1.2.2 Adalimumab Biosimilar
1.3 Global Adalimumab Market Size by Type
1.3.1 Global Adalimumab Market Size Overview by Type (2016-2027)
1.3.2 Global Adalimumab Historic Market Size Review by Type (2016-2021)
1.3.2.1 Global Adalimumab Sales Breakdown in Volume by Type (2016-2021)
1.3.2.2 Global Adalimumab Sales Breakdown in Value by Type (2016-2021)
1.3.2.3 Global Adalimumab Average Selling Price (ASP) by Type (2016-2021)
1.3.3 Global Adalimumab Forecasted Market Size by Type (2022-2027)
1.3.3.1 Global Adalimumab Sales Breakdown in Volume by Type (2022-2027)
1.3.3.2 Global Adalimumab Sales Breakdown in Value by Type (2022-2027)
1.3.3.3 Global Adalimumab Average Selling Price (ASP) by Type (2022-2027)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Adalimumab Sales Breakdown by Type (2016-2021)
1.4.2 Europe Adalimumab Sales Breakdown by Type (2016-2021)
1.4.3 Asia-Pacific Adalimumab Sales Breakdown by Type (2016-2021)
1.4.4 Latin America Adalimumab Sales Breakdown by Type (2016-2021)
1.4.5 Middle East and Africa Adalimumab Sales Breakdown by Type (2016-2021)
2 Global Adalimumab Market Competition by Company
2.1 Global Top Players by Adalimumab Sales (2016-2021)
2.2 Global Top Players by Adalimumab Revenue (2016-2021)
2.3 Global Top Players Adalimumab Price (2016-2021)
2.4 Global Top Manufacturers Adalimumab Manufacturing Base Distribution, Sales Area, Product Type
2.5 Adalimumab Market Competitive Situation and Trends
2.5.1 Adalimumab Market Concentration Rate (2016-2021)
2.5.2 Global 5 and 10 Largest Manufacturers by Adalimumab Sales and Revenue in 2020
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Adalimumab as of 2020)
2.7 Date of Key Manufacturers Enter into Adalimumab Market
2.8 Key Manufacturers Adalimumab Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Adalimumab Status and Outlook by Region
3.1 Global Adalimumab Market Size and CAGR by Region: 2016 VS 2021 VS 2026
3.2 Global Adalimumab Historic Market Size by Region
3.2.1 Global Adalimumab Sales in Volume by Region (2016-2021)
3.2.2 Global Adalimumab Sales in Value by Region (2016-2021)
3.2.3 Global Adalimumab Sales (Volume & Value) Price and Gross Margin (2016-2021)
3.3 Global Adalimumab Forecasted Market Size by Region
3.3.1 Global Adalimumab Sales in Volume by Region (2022-2027)
3.3.2 Global Adalimumab Sales in Value by Region (2022-2027)
3.3.3 Global Adalimumab Sales (Volume & Value), Price and Gross Margin (2022-2027)
4 Global Adalimumab by Application
4.1 Adalimumab Market Segment by Application
4.1.1 Adults
4.1.2 Children
4.2 Global Adalimumab Market Size by Application
4.2.1 Global Adalimumab Market Size Overview by Application (2016-2027)
4.2.2 Global Adalimumab Historic Market Size Review by Application (2016-2021)
4.2.2.1 Global Adalimumab Sales Breakdown in Volume, by Application (2016-2021)
4.2.2.2 Global Adalimumab Sales Breakdown in Value, by Application (2016-2021)
4.2.2.3 Global Adalimumab Average Selling Price (ASP) by Application (2016-2021)
4.2.3 Global Adalimumab Forecasted Market Size by Application (2022-2027)
4.2.3.1 Global Adalimumab Sales Breakdown in Volume, by Application (2022-2027)
4.2.3.2 Global Adalimumab Sales Breakdown in Value, by Application (2022-2027)
4.2.3.3 Global Adalimumab Average Selling Price (ASP) by Application (2022-2027)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Adalimumab Sales Breakdown by Application (2016-2021)
4.3.2 Europe Adalimumab Sales Breakdown by Application (2016-2021)
4.3.3 Asia-Pacific Adalimumab Sales Breakdown by Application (2016-2021)
4.3.4 Latin America Adalimumab Sales Breakdown by Application (2016-2021)
4.3.5 Middle East and Africa Adalimumab Sales Breakdown by Application (2016-2021)
5 North America Adalimumab by Country
5.1 North America Adalimumab Historic Market Size by Country
5.1.1 North America Adalimumab Sales in Volume by Country (2016-2021)
5.1.2 North America Adalimumab Sales in Value by Country (2016-2021)
5.2 North America Adalimumab Forecasted Market Size by Country
5.2.1 North America Adalimumab Sales in Volume by Country (2022-2027)
5.2.2 North America Adalimumab Sales in Value by Country (2022-2027)
6 Europe Adalimumab by Country
6.1 Europe Adalimumab Historic Market Size by Country
6.1.1 Europe Adalimumab Sales in Volume by Country (2016-2021)
6.1.2 Europe Adalimumab Sales in Value by Country (2016-2021)
6.2 Europe Adalimumab Forecasted Market Size by Country
6.2.1 Europe Adalimumab Sales in Volume by Country (2022-2027)
6.2.2 Europe Adalimumab Sales in Value by Country (2022-2027)
7 Asia-Pacific Adalimumab by Region
7.1 Asia-Pacific Adalimumab Historic Market Size by Region
7.1.1 Asia-Pacific Adalimumab Sales in Volume by Region (2016-2021)
7.1.2 Asia-Pacific Adalimumab Sales in Value by Region (2016-2021)
7.2 Asia-Pacific Adalimumab Forecasted Market Size by Region
7.2.1 Asia-Pacific Adalimumab Sales in Volume by Region (2022-2027)
7.2.2 Asia-Pacific Adalimumab Sales in Value by Region (2022-2027)
8 Latin America Adalimumab by Country
8.1 Latin America Adalimumab Historic Market Size by Country
8.1.1 Latin America Adalimumab Sales in Volume by Country (2016-2021)
8.1.2 Latin America Adalimumab Sales in Value by Country (2016-2021)
8.2 Latin America Adalimumab Forecasted Market Size by Country
8.2.1 Latin America Adalimumab Sales in Volume by Country (2022-2027)
8.2.2 Latin America Adalimumab Sales in Value by Country (2022-2027)
9 Middle East and Africa Adalimumab by Country
9.1 Middle East and Africa Adalimumab Historic Market Size by Country
9.1.1 Middle East and Africa Adalimumab Sales in Volume by Country (2016-2021)
9.1.2 Middle East and Africa Adalimumab Sales in Value by Country (2016-2021)
9.2 Middle East and Africa Adalimumab Forecasted Market Size by Country
9.2.1 Middle East and Africa Adalimumab Sales in Volume by Country (2022-2027)
9.2.2 Middle East and Africa Adalimumab Sales in Value by Country (2022-2027)
10 Company Profiles and Key Figures in Adalimumab Business
10.1 AbbVie
10.1.1 AbbVie Corporation Information
10.1.2 AbbVie Introduction and Business Overview
10.1.3 AbbVie Adalimumab Sales, Revenue and Gross Margin (2016-2021)
10.1.4 AbbVie Adalimumab Products Offered
10.1.5 AbbVie Recent Development
10.2 Amgen
10.2.1 Amgen Corporation Information
10.2.2 Amgen Introduction and Business Overview
10.2.3 Amgen Adalimumab Sales, Revenue and Gross Margin (2016-2021)
10.2.4 AbbVie Adalimumab Products Offered
10.2.5 Amgen Recent Development
10.3 Sandoz
10.3.1 Sandoz Corporation Information
10.3.2 Sandoz Introduction and Business Overview
10.3.3 Sandoz Adalimumab Sales, Revenue and Gross Margin (2016-2021)
10.3.4 Sandoz Adalimumab Products Offered
10.3.5 Sandoz Recent Development
10.4 Boehringer Ingelheim
10.4.1 Boehringer Ingelheim Corporation Information
10.4.2 Boehringer Ingelheim Introduction and Business Overview
10.4.3 Boehringer Ingelheim Adalimumab Sales, Revenue and Gross Margin (2016-2021)
10.4.4 Boehringer Ingelheim Adalimumab Products Offered
10.4.5 Boehringer Ingelheim Recent Development
10.5 Mylan
10.5.1 Mylan Corporation Information
10.5.2 Mylan Introduction and Business Overview
10.5.3 Mylan Adalimumab Sales, Revenue and Gross Margin (2016-2021)
10.5.4 Mylan Adalimumab Products Offered
10.5.5 Mylan Recent Development
10.6 Biogen
10.6.1 Biogen Corporation Information
10.6.2 Biogen Introduction and Business Overview
10.6.3 Biogen Adalimumab Sales, Revenue and Gross Margin (2016-2021)
10.6.4 Biogen Adalimumab Products Offered
10.6.5 Biogen Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Adalimumab Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Adalimumab Industrial Chain Analysis
11.4 Adalimumab Market Dynamics
11.4.1 Industry Trends
11.4.2 Market Drivers
11.4.3 Market Challenges
11.4.4 Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Adalimumab Distributors
12.3 Adalimumab Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1.1 Adalimumab Product Overview
1.2 Adalimumab Market Segment by Type
1.2.1 Adalimumab
1.2.2 Adalimumab Biosimilar
1.3 Global Adalimumab Market Size by Type
1.3.1 Global Adalimumab Market Size Overview by Type (2016-2027)
1.3.2 Global Adalimumab Historic Market Size Review by Type (2016-2021)
1.3.2.1 Global Adalimumab Sales Breakdown in Volume by Type (2016-2021)
1.3.2.2 Global Adalimumab Sales Breakdown in Value by Type (2016-2021)
1.3.2.3 Global Adalimumab Average Selling Price (ASP) by Type (2016-2021)
1.3.3 Global Adalimumab Forecasted Market Size by Type (2022-2027)
1.3.3.1 Global Adalimumab Sales Breakdown in Volume by Type (2022-2027)
1.3.3.2 Global Adalimumab Sales Breakdown in Value by Type (2022-2027)
1.3.3.3 Global Adalimumab Average Selling Price (ASP) by Type (2022-2027)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Adalimumab Sales Breakdown by Type (2016-2021)
1.4.2 Europe Adalimumab Sales Breakdown by Type (2016-2021)
1.4.3 Asia-Pacific Adalimumab Sales Breakdown by Type (2016-2021)
1.4.4 Latin America Adalimumab Sales Breakdown by Type (2016-2021)
1.4.5 Middle East and Africa Adalimumab Sales Breakdown by Type (2016-2021)
2 Global Adalimumab Market Competition by Company
2.1 Global Top Players by Adalimumab Sales (2016-2021)
2.2 Global Top Players by Adalimumab Revenue (2016-2021)
2.3 Global Top Players Adalimumab Price (2016-2021)
2.4 Global Top Manufacturers Adalimumab Manufacturing Base Distribution, Sales Area, Product Type
2.5 Adalimumab Market Competitive Situation and Trends
2.5.1 Adalimumab Market Concentration Rate (2016-2021)
2.5.2 Global 5 and 10 Largest Manufacturers by Adalimumab Sales and Revenue in 2020
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Adalimumab as of 2020)
2.7 Date of Key Manufacturers Enter into Adalimumab Market
2.8 Key Manufacturers Adalimumab Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Adalimumab Status and Outlook by Region
3.1 Global Adalimumab Market Size and CAGR by Region: 2016 VS 2021 VS 2026
3.2 Global Adalimumab Historic Market Size by Region
3.2.1 Global Adalimumab Sales in Volume by Region (2016-2021)
3.2.2 Global Adalimumab Sales in Value by Region (2016-2021)
3.2.3 Global Adalimumab Sales (Volume & Value) Price and Gross Margin (2016-2021)
3.3 Global Adalimumab Forecasted Market Size by Region
3.3.1 Global Adalimumab Sales in Volume by Region (2022-2027)
3.3.2 Global Adalimumab Sales in Value by Region (2022-2027)
3.3.3 Global Adalimumab Sales (Volume & Value), Price and Gross Margin (2022-2027)
4 Global Adalimumab by Application
4.1 Adalimumab Market Segment by Application
4.1.1 Adults
4.1.2 Children
4.2 Global Adalimumab Market Size by Application
4.2.1 Global Adalimumab Market Size Overview by Application (2016-2027)
4.2.2 Global Adalimumab Historic Market Size Review by Application (2016-2021)
4.2.2.1 Global Adalimumab Sales Breakdown in Volume, by Application (2016-2021)
4.2.2.2 Global Adalimumab Sales Breakdown in Value, by Application (2016-2021)
4.2.2.3 Global Adalimumab Average Selling Price (ASP) by Application (2016-2021)
4.2.3 Global Adalimumab Forecasted Market Size by Application (2022-2027)
4.2.3.1 Global Adalimumab Sales Breakdown in Volume, by Application (2022-2027)
4.2.3.2 Global Adalimumab Sales Breakdown in Value, by Application (2022-2027)
4.2.3.3 Global Adalimumab Average Selling Price (ASP) by Application (2022-2027)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Adalimumab Sales Breakdown by Application (2016-2021)
4.3.2 Europe Adalimumab Sales Breakdown by Application (2016-2021)
4.3.3 Asia-Pacific Adalimumab Sales Breakdown by Application (2016-2021)
4.3.4 Latin America Adalimumab Sales Breakdown by Application (2016-2021)
4.3.5 Middle East and Africa Adalimumab Sales Breakdown by Application (2016-2021)
5 North America Adalimumab by Country
5.1 North America Adalimumab Historic Market Size by Country
5.1.1 North America Adalimumab Sales in Volume by Country (2016-2021)
5.1.2 North America Adalimumab Sales in Value by Country (2016-2021)
5.2 North America Adalimumab Forecasted Market Size by Country
5.2.1 North America Adalimumab Sales in Volume by Country (2022-2027)
5.2.2 North America Adalimumab Sales in Value by Country (2022-2027)
6 Europe Adalimumab by Country
6.1 Europe Adalimumab Historic Market Size by Country
6.1.1 Europe Adalimumab Sales in Volume by Country (2016-2021)
6.1.2 Europe Adalimumab Sales in Value by Country (2016-2021)
6.2 Europe Adalimumab Forecasted Market Size by Country
6.2.1 Europe Adalimumab Sales in Volume by Country (2022-2027)
6.2.2 Europe Adalimumab Sales in Value by Country (2022-2027)
7 Asia-Pacific Adalimumab by Region
7.1 Asia-Pacific Adalimumab Historic Market Size by Region
7.1.1 Asia-Pacific Adalimumab Sales in Volume by Region (2016-2021)
7.1.2 Asia-Pacific Adalimumab Sales in Value by Region (2016-2021)
7.2 Asia-Pacific Adalimumab Forecasted Market Size by Region
7.2.1 Asia-Pacific Adalimumab Sales in Volume by Region (2022-2027)
7.2.2 Asia-Pacific Adalimumab Sales in Value by Region (2022-2027)
8 Latin America Adalimumab by Country
8.1 Latin America Adalimumab Historic Market Size by Country
8.1.1 Latin America Adalimumab Sales in Volume by Country (2016-2021)
8.1.2 Latin America Adalimumab Sales in Value by Country (2016-2021)
8.2 Latin America Adalimumab Forecasted Market Size by Country
8.2.1 Latin America Adalimumab Sales in Volume by Country (2022-2027)
8.2.2 Latin America Adalimumab Sales in Value by Country (2022-2027)
9 Middle East and Africa Adalimumab by Country
9.1 Middle East and Africa Adalimumab Historic Market Size by Country
9.1.1 Middle East and Africa Adalimumab Sales in Volume by Country (2016-2021)
9.1.2 Middle East and Africa Adalimumab Sales in Value by Country (2016-2021)
9.2 Middle East and Africa Adalimumab Forecasted Market Size by Country
9.2.1 Middle East and Africa Adalimumab Sales in Volume by Country (2022-2027)
9.2.2 Middle East and Africa Adalimumab Sales in Value by Country (2022-2027)
10 Company Profiles and Key Figures in Adalimumab Business
10.1 AbbVie
10.1.1 AbbVie Corporation Information
10.1.2 AbbVie Introduction and Business Overview
10.1.3 AbbVie Adalimumab Sales, Revenue and Gross Margin (2016-2021)
10.1.4 AbbVie Adalimumab Products Offered
10.1.5 AbbVie Recent Development
10.2 Amgen
10.2.1 Amgen Corporation Information
10.2.2 Amgen Introduction and Business Overview
10.2.3 Amgen Adalimumab Sales, Revenue and Gross Margin (2016-2021)
10.2.4 AbbVie Adalimumab Products Offered
10.2.5 Amgen Recent Development
10.3 Sandoz
10.3.1 Sandoz Corporation Information
10.3.2 Sandoz Introduction and Business Overview
10.3.3 Sandoz Adalimumab Sales, Revenue and Gross Margin (2016-2021)
10.3.4 Sandoz Adalimumab Products Offered
10.3.5 Sandoz Recent Development
10.4 Boehringer Ingelheim
10.4.1 Boehringer Ingelheim Corporation Information
10.4.2 Boehringer Ingelheim Introduction and Business Overview
10.4.3 Boehringer Ingelheim Adalimumab Sales, Revenue and Gross Margin (2016-2021)
10.4.4 Boehringer Ingelheim Adalimumab Products Offered
10.4.5 Boehringer Ingelheim Recent Development
10.5 Mylan
10.5.1 Mylan Corporation Information
10.5.2 Mylan Introduction and Business Overview
10.5.3 Mylan Adalimumab Sales, Revenue and Gross Margin (2016-2021)
10.5.4 Mylan Adalimumab Products Offered
10.5.5 Mylan Recent Development
10.6 Biogen
10.6.1 Biogen Corporation Information
10.6.2 Biogen Introduction and Business Overview
10.6.3 Biogen Adalimumab Sales, Revenue and Gross Margin (2016-2021)
10.6.4 Biogen Adalimumab Products Offered
10.6.5 Biogen Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Adalimumab Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Adalimumab Industrial Chain Analysis
11.4 Adalimumab Market Dynamics
11.4.1 Industry Trends
11.4.2 Market Drivers
11.4.3 Market Challenges
11.4.4 Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Adalimumab Distributors
12.3 Adalimumab Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
